Tagged with EG

UAE Amr Seif outlines Astellas’ progress into becoming a focused oncology speciality player in the Middle East and Africa, in line with the company’s global Corporate Strategic Plan 2021 (CSP2021). He also touches on key market trends in MEA, including regulatory developments, the rise of private insurance, and the growing importance…

Europe As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for the coming year, including the lessons to be taken from the pandemic response, why antimicrobial resistance must not be neglected,…

UAE Tabuk Pharmaceuticals is a Saudi success story, now established as one of the GCC region’s leading private pharmaceutical companies. Gulf Manager Ossama Salah Ramadan explains what attracted him to the firm, his current strategic objectives in line with the company’s global growth goals, and some of the key local trends…

Greece Angelini Pharma’s Gabriele Jannis draws on his experience in both Russia and Romania to highlight some of the key challenges for European mid-caps like Angelini in Greece, the importance of CEE countries in the company’s internationalisation efforts, and his hopes for future reform that increases the level of certainty in…

Belgium Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach to oncology with a focus on hard-to-treat cancers, as well as its focus on patient centricity   In oncology, we…

Belgium Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11 years in position, and highlights some of the key issues on her agenda as pharma.be’s SME subgroup chair.   The…

Belgium Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on top of the rapidly evolving technologies being brought forward today, and the significance of a new early access programme for…

Romania Part of PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece is focused on the expenditure control and cost containment policies that currently exist in the Romanian pharma market. Buy The Pharma Legal Handbook: Market Access & HTA – Romania here for £359.   1.…

UAE Dr Omar Hallak talks about the journey towards establishing a cardiovascular center of excellence at King’s College Hospital in the UAE and discusses advancements made in the field of cardiology in the country, particularly in terms of access to care, research, and technology.   With the advancements in technology and…

Belgium Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the company’s biosimilar portfolio has the potential to contribute to significant savings for the healthcare system.   Improving the evaluation process…

Europe In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the Agency’s approach to antimicrobial resistance, and highlights how it hopes to contribute to a stronger European clinical trials ecosystem.  …

Greece Yvoni Papastelatou outlines Sanofi’s commitment to Greece, where the multinational firm has a strong and diverse team, a burgeoning clinical trial footprint, and is rolling out the global ‘play to win’ strategy, with a common ambition to leverage science and innovation. She also touches on the access challenges in the…